The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
News may already be in the pipeline.....but how long is the pipe? Usually, when news is commonly thought to be 'imminent'...especially after a huge drop in sentiment, pi's tend to feel that they were 'clever' to hold off for so long. In effect 'getting it right'. That's when they begin to think......"My luck could run out and i'll miss the boat"........that moment may be imminent also........TIMING....good luck all. ...and something about rampers and those incorrigible trolls..... When I was in 'clean' stocks without the trolling i made a lot of money by being fair and honest. If the stocks weren't good why did we all make on them, not just me but hundreds of investors. Anyone can make money.if you get into the best stocks that are not trashed by trolls. 'Share-killers' do just that, don't argue the point, just believe it. http://pumpedordumped.com/rampchecker/rampchecktopramper.php So now i'm up to 3rd...in a way that is a compliment. Most posters that read my posts know that i never deramp, why should i change now? buy hold .......P&D List .....and for balance....four of my holdings are not mentioned...why? Because i don't post on them...and if i don't post regular this stupid compilation assumes i have p&d and gone ? I'm in 3rd place and still holding all the stocks listed !!
I totally agree COS their products are very good. IMO
Once news of US deals are confirmed......can't see their trip being fruitless. Then of course will come the looney boys thinking they know it all and spout off about how we should dump all our shares....COS it's true. innit? lol
Good product imo.Just need some sales now.
https://drive.google.com/file/d/1-4iopd4k7-mlYvJSiogYKAECXwmvErtg/view alt link https://goo.gl/MCU8fv
Thanks Tino......was beginning to think this was completely abandoned...gla
Lol i'm guessing it's a bit slow for your liking. Hopefully they come back from the USA with some new orders and we can watch this rise. I've been in cos a while and in my opinion it will go places soon.
Anyone heard of Collagen......by the time any one posts i'll be showing my kids how to get their pension credits sorted...ffs
http://www.proactiveinvestors.co.uk/companies/news/191961 Collagen Solutions soars after positive outcome to epic ChondroMimetic implants study 13:25 21 Feb 2018 "The long-term quantitative MRI data of cartilage repair volume and tissue quality in patients who were treated with ChondroMimetic are extremely attractive," said the appropriately named Dr Alan Getgood, an orthopaedic surgeon who was involved in ChondroMimetic's early development Knee joints The submission for CE Mark approval is targeted for the second half of 2018 Collagen Solutions PLC (LON:COS) was the London market's top gainer on Wednesday after it said it is to make an initial submission for a CE mark after positive results from a clinical study of ChondroMimetic implants. In early afterrnoon trading, Collagen shares were up 18.5%, or 0.5p at 3.2p. The developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine announced successful results from an eight-year extension clinical study of 15 patients who received ChondroMimetic implants as a bone and cartilage scaffold for the repair of cartilage defects in the knee. WATCH: Collagen Solutions applies for European approval after successful ChondroMimetic study Collagen's shares opened 29% higher at 3.49p as the company revealed quantitative three-dimensional magnetic resonance imaging analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage. The eight-year study found there was an improvement in patients' clinical symptoms, including alleviation of pain; improved function; and increased activity level. The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient-reported outcome measure, showed outcomes following the ChondroMimetic procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies, Collagen observed. The regenerative medtech said the study leaves ChondroMimetic positioned as �the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data�. With more than a million surgical procedures taking place each year in the US and Europe to treat cartilage defects of the knee, the market for ChondroMimetic is enormous; Collagen reckons at least 30-40% of these operations would be suitable for ChondroMimetic. **more.... https://goo.gl/mdVSFp
Hopefully some good sales and cotracts at the conference in the states. Maybe even a new partner.exciting week imo.
Read the same, unsurprising. Minor companies get used or are sometimes complicit in scams. Collagen Solutions a good egg as far as I know?
The money laundering funds would, according to the FBI, be accumulated by the share price manipulation and distorting trading volumes- not paid for. Have a read. Shocking stuff. Beaufort Securities https://www.justice.gov/usao-edny/pr/six-individuals-and-four-corporate-defendants-indicted-50-million-international This says that the FBI have arrested 6 people from Beaufort for conspiracy to defraud and for money laundering in the US. The money laundering was to be paid for from the proceeds of funds gained from share price manipulation and distorting the volumes of trades!
failed link....try this- https://goo.gl/tqib33
Collagen Solutions Closing in on first proprietary product http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/26.02.18-closing-in-on-first-proprietary-product.pdf Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Eight years after implantation, clinical outcomes with ChondroMimetic were at least as good as could be expected, and better than those published in the literature for alternative methods of cartilage repair. * Strategy: Management has embarked on an investment strategy through a series of initiatives to increase the growth opportunities. This strategy is moving COS from a reliable, quality collagen supplier to one that also has proprietary products that will make it into profitable, and cash-generative, at a faster pace. * ChondroMimetic: Best described as a clever, bi-layered and easy-to-use sponge that allows the regeneration of cartilage and bone, the product has good provenance having received CE Mark in 2008 and implanted into ca.600 patients. However, for reasons prior to COS�s ownership, the CE Mark lapsed. * Eight-year outcomes: As part of the process of re-applying for CE Mark, 15/17 patients from the original trial in 2009-10 have been reassessed. The ChondroMimetic scaffold produced a sustained long-term regeneration of cartilage, undifferentiated from native cartilage, with improved clinical symptoms. * Next steps: COS has initiated the submission for CE Mark, which will be supplemented by these data, allowing the re-issuance of CE Mark during 2H�18. Meanwhile, COS is continuing active discussions with potential commercial partners, on both a local (e.g. deal for South Korea) and more global basis. * Investment summary: ChondroMimetic fulfils COS�s stated strategy to move further up the value chain. These exceptional eight-year clinical outcomes will significantly differentiate it from competing therapies. In order to maximise returns, COS needs to conclude commercial arrangements in readiness for a European launch in 2H�18, and with a strong partner capable of undertaking the trials needed to launch the product in the US. Presentation slides: https://drive.google.com/file/d/1-4iopd4k7-mlYvJSiogYKAECXwmvErtg/view
The wider spread should boost the sp. Unlike N4p which has traders buying and then quickly selling for a short term (2 days or less) profit - collagen solutions will have buyers who hold. This reduces the number of shares available and consequently increases the price. The CEO initially invested at 12p. There have been further purchases by the directors at 5p and around 3p. If there is the suggested take over approach it is only going to happen at a marked increase of 12p. However, in my opinion this is a company that are offering surgery at a cost of 10% of the typical price. Like entrepreneurs say 'stack em high and sell them cheap '. This will soon be a world leader with a business model that makes a fortune.
Jamal Rushdy, Chief Executive Officer of Collagen Solutions #COS discusses their positive eight-year results of their ChondroMimetic� Cartilage Repair Clinical Study. https://audioboom.com/posts/6689600-jamal-rushdy-chief-executive-officer-of-collagen-solutions-cos-220218 *Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. *The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic. *The Company�s products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
http://www.hl.co.uk/news/2018/2/26/cash-rich-investors-are-hungry-for-deals-as-superreturn-begins One possible outcome of the successful trial is that someone will buy COS and take it private.
http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/26.02.18-closing-in-on-first-proprietary-product.pdf Collagen Solutions Closing in on first proprietary product Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate of growth, including global commercial infrastructure and development of a pipeline of finished medical devices, the first of which will be ChondroMimetic for repair of small cartilage lesions. Eight years after implantation, clinical outcomes with ChondroMimetic were at least as good as could be expected, and better than those published in the literature for alternative methods of cartilage repair. http://ir.collagensolutions.com/content/news/ir_news.asp
IF any one on here goes tonite.i wonder if you would post anything gleaned that may ber useful? London Investor Symposium Monday 26 February 2018 Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds and cardiovascular, is delighted to confirm that it will hosting an afternoon presentation for investors on Monday, 26 February 2018. Jamal Rushdy, CEO of the Company, will give an update on recent news and key milestones expected this year on ChondroMimetric�, the Company's proprietary product, a minimally-invasive surgically placed scaffold for the repair of knee cartilage defects. Jamal will also provide a summary of the Company's core business activities over the next period. This will also be an opportunity for investors to be introduced to Hilary Spence, who has recently been appointed as CFO. The event will take place in the Copper Bar, upstairs at Balls Brothers, 6 Adams Court, Old Broad St, London, EC2N 1DX at 5.30pm for a 5.45pm start.
It needs to, just tried to take some profit on a good run and they only offered 4.65p while asking 5.25 if buying. Might try later but underwhelmed by sell price given the news and demand for shares.
Presentation later today. Anyone going? http://ir.collagensolutions.com/content/news/2018/060218.asp
Interview on Friday, but looks like it hasn't been posted here yet : https://audioboom.com/posts/6689600-jamal-rushdy-chief-executive-officer-of-collagen-solutions-cos-220218
Which way? Would not be surprised to see a drop back in sp as this last week has been a bit frothy. Remain pleased by the science news and holding my shares.
Mms treating thisb with tender care ...'COS we all know which way this is going, gla
Hardman research is paid for by the company so independent research is more credible, esp for sales forecasts